TP53 and breast cancer: Although loss of ER expression is found in ~25% of PDO derived from ER+ tumour samples, likely secondary to establishing PDO culture, reduced ER expression in metastases from ER+ primary breast cancers is also reported43–45, and linked to more frequent TP53 mutation in endocrine therapy-resistant metastatic diease46.